日本呼吸器学会

日本緩和医療学会

Effects of <i>KRAS</i>, <i>STK11</i>, <i>KEAP1</i>, and <i>TP53</i> mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

Liang, Y; Maeda, O; Kondo, C; Nishida, K; Ando, Y

PLOS ONE   Vol. 19 ( 7 ) page： e0307580   2024.7

Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.

Kato T, Kawaguchi T, Funakoshi T, Fujiwara Y, Yasuda Y, Ando Y

Cancer diagnosis & prognosis   Vol. 4 ( 4 ) page： 390 - 395   2024.7

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring <i>BRAF</i><SUP>V600E</SUP> mutation

Takano, Y; Shimokata, T; Urakawa, H; Kikumori, T; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 13 ( 3 ) page： 209 - 213   2024.7

Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older

Yagishita, S; Yamanaka, Y; Kurata, T; Watanabe, K; Hosomi, Y; Horinouchi, H; Ohe, Y; Nakahara, Y; Naoki, K; Asao, T; Takahashi, K; Saeki, S; Sakagami, T; Nakashima, K; Tsubata, Y; Fujita, Y; Wakui, H; Furuta, M; Konishi, JS; Ohuchi, M; Ando, Y; Mizugaki, H; Hamada, A

CLINICAL PHARMACOLOGY & THERAPEUTICS     2024.6

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Kobayashi, T; Iwama, S; Yamagami, A; Izuchi, T; Suzuki, K; Otake, K; Yasuda, Y; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Nishio, N; Mori, S; Shimokata, T; Sano, T; Niimi, K; Yoshikawa, N; Akamatsu, S; Ando, Y; Akiyama, M; Sone, M; Ishii, M; Arima, H

CANCER IMMUNOLOGY IMMUNOTHERAPY   Vol. 73 ( 8 ) page： 146   2024.6

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team

Ito, T; Mizuno, K; Yamamoto, T; Yasuda, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Hama, M; Kataoka, T; Shimokata, T; Ando, Y; Kawashima, H

HEPATOLOGY RESEARCH     2024.4

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

Ushijima, F; Hase, T; Yamashita, Y; Kim, H; Shimokata, T; Kondo, C; Sato, T; Baba, T; Watanabe, S; Futamura, K; Ando, Y; Mizuno, M; Ishii, M

INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 13 ( 2 ) page： 88 - 92   2024.4

Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review

Kato, T; Kurasawa, S; Takezawa, K; Fujiwara, Y; Yasuda, Y; Ando, Y

ANTICANCER RESEARCH   Vol. 44 ( 3 ) page： 889 - 894   2024.3

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (oct, 10.1007/s10157-023-02415-0, 2022)

Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 28 ( 2 ) page： 123 - 124   2024.2

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 28 ( 2 ) page： 85 - 122   2024.2

Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer

Liang, Y; Maeda, O; Miyata, K; Kanda, M; Sugita, S; Shimizu, D; Nishida, K; Kodera, Y; Ando, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 93 ( 2 ) page： 121 - 127   2024.2

Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer

Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Machida, N; Sakai, M; Kobayashi, D; Teramoto, H; Ishiyama, A; Sato, B; Oshima, T; Kajikawa, M; Matsushita, H; Ishigure, K; Yamashita, K; Fujitake, S; Sueoka, S; Asada, T; Shimizu, D; Sugita, S; Kuwatsuka, Y; Maeda, O; Furune, S; Murotani, K; Ando, Y; Ebata, T; Kodera, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 86 ( 1 ) page： 43 - 51   2024.2

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

Liang, Y; Maeda, O; Ando, Y

JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 54 ( 4 ) page： 365 - 375   2024.1

Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer

Maeda, O; Furune, S; Kanda, M; Miyata, K; Shimizu, D; Sugita, S; Nishida, K; Ando, M; Kodera, Y; Ando, Y

CANCER MEDICINE   Vol. 13 ( 2 ) page： e6974   2024.1

Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma

Liang, Y; Maeda, O; Shimokata, T; Yokota, K; Koike, H; Sakai, T; Ikuta, K; Urakawa, H; Nishida, Y; Akiyama, M; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 13 ( 1 ) page： 63 - 67   2024.1

Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial

Furune, S; Ando, Y

LUNG CANCER   Vol. 186   page： 107416   2023.12

Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA &gt; 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer

Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Furukawa, K; Maeda, O; Shimizu, D; Sugita, S; Kakushima, N; Furune, S; Kawashima, H; Ando, Y; Ebata, T; Kodera, Y

CANCERS   Vol. 15 ( 21 )   2023.11

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer

Hatta, T; Hase, T; Hara, T; Kimura, T; Kojima, E; Abe, T; Horio, Y; Goto, Y; Ozawa, N; Yogo, N; Shibata, H; Shimokata, T; Oguri, T; Yamamoto, M; Yanagisawa, K; Ando, M; Ando, Y; Kondo, M; Ishii, M; Hasegawa, Y

CANCER MEDICINE   Vol. 12 ( 15 ) page： 15955 - 15969   2023.8

A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy

Liang, Y; Maeda, O; Miyata, K; Tanaka, C; Kanda, M; Shimizu, D; Fukaya, M; Koike, M; Kodera, Y; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2023.7

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

Yamamoto, T; Mizuno, K; Ito, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Ishikawa, T; Kanamori, A; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Ishii, M; Sone, M; Ando, Y; Akiyama, M; Ishigami, M; Kawashima, H

INVESTIGATIONAL NEW DRUGS   Vol. 41 ( 3 ) page： 512 - 521   2023.6

Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer

Liang, Y; Maeda, O; Miyata, K; Kanda, M; Shimizu, D; Sugita, S; Okada, T; Ito, J; Kawamura, M; Ishihara, S; Nakatochi, M; Ando, M; Kodera, Y; Ando, Y

MOLECULAR AND CLINICAL ONCOLOGY   Vol. 18 ( 4 ) page： 34   2023.4

Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury

Yamamoto, T; Morooka, H; Ito, T; Ishigami, M; Mizuno, K; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Yokota, K; Hase, T; Maeda, O; Hashimoto, N; Ando, Y; Akiyama, M; Kawashima, H

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   Vol. 38 ( 2 ) page： 251 - 258   2023.2

Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study

Maeda, O; Fukaya, M; Koike, M; Miyata, K; Kanda, M; Nishida, K; Ando, M; Kodera, Y; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   Vol. 18 ( 6 ) page： 578 - 585   2022.12

Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment

Maeda, O; Matsuoka, A; Yanagawa, M; Muroyama, Y; Watanabe, K; Liang, Y; Ishikawa, T; Ohno, E; Kawashima, H; Umegaki, H; Kuzuya, M; Ando, Y

JOURNAL OF GERIATRIC ONCOLOGY   Vol. 13 ( 8 ) page： 1260 - 1263   2022.11

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

Morita, S; Minami, H; Mitsuma, A; Toyoda, M; Kiyota, N; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   Vol. 18 ( 5 ) page： E427 - E434   2022.10

Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade

Kobayashi, T; Iwama, S; Yamagami, A; Yasuda, Y; Okuji, T; Ito, M; Zhou, X; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Ito, T; Kikumori, T; Inoue, M; Ando, Y; Masuda, N; Kawashima, H; Hashimoto, N; Arima, H

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 10 ) page： E4115 - E4123   2022.9

Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association

Yamaguchi, T; Sugiyama, Y; Tanaka, T; Kimura, T; Yumura, Y; Nakano, M; Sugiyama, T; Miura, N; Goya, M; Yamamoto, A; Takahashi, S; Miura, Y; Tsuzuki, T; Masumori, N; Nishiyama, H; Yao, MS; Koie, T; Miyake, H; Saika, T; Saito, S; Akimoto, T; Tamada, T; Ando, Y; Takahashi, S; Suzuki, T; Hinotsu, S; Kamba, T

INTERNATIONAL JOURNAL OF UROLOGY   Vol. 29 ( 8 ) page： 780 - 792   2022.8

Clinical impact of standardized creatinine on dose adjustment of capecitabine

Ito, A; Ichikawa, K; Miyazaki, M; Sagara, A; Motegi, T; Ando, Y; Senzaki, K; Nagai, T; Yamada, K

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 84 ( 3 ) page： 547 - 553   2022.8

Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.

Mitsuma A, Ito Y, Shimokata T, Tanaka C, Uehara K, Nakayama G, Terasaki H, Ando Y

Cancer diagnosis & prognosis   Vol. 2 ( 3 ) page： 330 - 335   2022.5

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline

Iwama, S; Kobayashi, T; Yasuda, Y; Okuji, T; Ito, M; Ando, M; Zhou, X; Yamagami, A; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Takagi, H; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Wakahara, K; Yokota, K; Kato, M; Nishio, N; Tanaka, C; Miyata, K; Ogura, A; Ito, T; Sawada, T; Shimokata, T; Niimi, K; Ohka, F; Ishigami, M; Gotoh, M; Hashimoto, N; Saito, R; Kiyoi, H; Kajiyama, H; Ando, Y; Hibi, H; Sone, M; Akiyama, M; Kodera, Y; Arima, H

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 4 ) page： E1620 - E1630   2022.3

Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade

Miyai, Y; Sugiyama, D; Hase, T; Asai, N; Taki, T; Nishida, K; Fukui, T; Chen-Yoshikawa, TF; Kobayashi, H; Mii, S; Shiraki, Y; Hasegawa, Y; Nishikawa, H; Ando, Y; Takahashi, M; Enomoto, A

LIFE SCIENCE ALLIANCE   Vol. 5 ( 6 )   2022.3

[Chemotherapy for Older Patients with Cancer].

Mitsuma A, Ando Y

Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 49 ( 1 ) page： 13 - 18   2022.1

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

Takano, Y; Furune, S; Miyai, Y; Morita, S; Inoue, M; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page： 67 - 70   2022.1

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

Furune, S; Kondo, C; Takano, Y; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page： 49 - 49   2022.1

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Furune, S; Kondo, C; Takano, Y; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page： 46 - 48   2022.1

COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective

Nishiwaki, S; Ando, Y

FRONTIERS IN MEDICINE   Vol. 8   page： 812370   2021.12

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

Kanda, M; Shimizu, D; Miyata, K; Maeda, O; Tanaka, C; Inokawa, Y; Hattori, N; Hayashi, M; Ando, M; Kuwatsuka, Y; Murotani, K; Nakayama, G; Koike, M; Ando, Y; Ebata, T; Kodera, Y

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS   Vol. 24   page： 100853   2021.12

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

Schöffski, P; Concin, N; Suarez, C; Subbiah, V; Ando, Y; Ruan, SL; Wagner, JP; Mansfield, K; Zhu, X; Origuchi, S; DiDominick, S; Bialucha, CU; Faris, JE; Tran, B

ONCOLOGY RESEARCH AND TREATMENT   Vol. 44 ( 10 ) page： 547 - 556   2021.10

Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

Ito, T; Ishigami, M; Yamamoto, T; Mizuno, K; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Kawashima, H; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Kato, M; Hashimoto, N; Hibi, H; Kodera, Y; Sone, M; Ando, Y; Akiyama, M; Shimoyama, Y; Fujishiro, M

HEPATOLOGY INTERNATIONAL   Vol. 15 ( 5 ) page： 1278 - 1287   2021.10

Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

Kazama, S; Morimoto, R; Kimura, Y; Shibata, N; Ozaki, R; Araki, T; Mizutani, T; Oishi, H; Arao, Y; Kuwayama, T; Hiraiwa, H; Kondo, T; Furusawa, K; Shimokata, T; Okumura, T; Bando, YK; Ando, Y; Murohara, T

CARDIO-ONCOLOGY   Vol. 7 ( 1 ) page： 26   2021.7

Guidelines for clinical evaluation of anti-cancer drugs

Minami, H; Kiyota, N; Kimbara, S; Ando, Y; Shimokata, T; Ohtsu, A; Fuse, N; Kuboki, Y; Shimizu, T; Yamamoto, N; Nishio, K; Kawakami, Y; Nihira, SI; Sase, K; Nonaka, T; Takahashi, H; Komori, Y; Kiyohara, K

CANCER SCIENCE   Vol. 112 ( 7 ) page： 2563 - 2577   2021.7

A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

Takano, Y; Furune, S; Morita, S; Inoue, M; Shimokata, T; Sugishita, M; Mitsuma, A; Osamu, M; Ando, Y

ANNALS OF ONCOLOGY   Vol. 32   page： S354 - S354   2021.7

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Wick, A; Bähr, O; Schuler, M; Rohrberg, K; Chawla, SP; Janku, F; Schiff, D; Heinemann, V; Narita, Y; Lenz, HJ; Ikeda, M; Ando, Y; Wick, W; Steinbach, JP; Burger, MC; Wenger, K; Lassen, U; Sankhala, KK; Roggia, C; Genvresse, I; Munhoz, C; Rentzsch, C; Reschke, S; Langer, S; Wagner, M; Kaulfuss, S; Cai, C; Lagkadinou, E; Jeffers, M; Peña, C; Tabatabai, G

CLINICAL CANCER RESEARCH   Vol. 27 ( 10 ) page： 2723 - 2733   2021.5

Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Minami, H; Doi, T; Toyoda, M; Imamura, Y; Kiyota, N; Mitsuma, A; Shimokata, T; Naito, Y; Matsubara, N; Tajima, T; Tokushige, K; Ishihara, K; Cameron, S; Ando, Y

CANCER SCIENCE   Vol. 112 ( 2 ) page： 725 - 733   2021.2

Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

Nakayama, G; Takano, N; Taniguchi, H; Ishigure, K; Yokoyama, H; Teramoto, H; Hashimoto, R; Sakai, M; Ishiyama, A; Kinoshita, T; Hayashi, N; Nakamura, M; Hattori, N; Sato, Y; Umeda, S; Uehara, K; Aiba, T; Sonohara, F; Hayashi, M; Kanda, M; Kobayashi, D; Tanaka, C; Yamada, S; Koike, M; Fujiwara, M; Murotani, K; Ando, M; Ando, Y; Muro, K; Kodera, Y

EUROPEAN JOURNAL OF CANCER   Vol. 144   page： 61 - 71   2021.2

Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study

Tsubata, Y; Shinomiya, S; Inoue, K; Ishikawa, N; Saito, R; Nakashima, K; Hotta, K; Hamada, A; Nagashima, F; Ando, Y; Morita, S; Kobayashi, K; Isobe, T

BMC GERIATRICS   Vol. 21 ( 1 ) page： 74   2021.1

PhaseIIclinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors

Nishida, Y; Urakawa, H; Nakayama, R; Kobayashi, E; Ozaki, T; Ae, K; Matsumoto, Y; Tsuchiya, H; Goto, T; Hiraga, H; Naka, N; Takahashi, S; Ando, Y; Ando, M; Kuwatsuka, Y; Hamada, S; Ueda, T; Kawai, A

INTERNATIONAL JOURNAL OF CANCER   Vol. 148 ( 1 ) page： 140 - 149   2021.1

Chemotherapy for biliary tract cancer: real-world experience in a single institute

Maeda, O; Ebata, T; Shimokata, T; Matsuoka, A; Inada-Inoue, M; Morita, S; Takano, Y; Urakawa, H; Miyai, Y; Sugishita, M; Mitsuma, A; Ando, M; Mizuno, T; Nagino, M; Ando, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page： 725 - 733   2020.11

What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?

Ogura, A; Uehara, K; Aiba, T; Hattori, N; Nakayama, G; Maeda, O; Ando, Y; Kodera, Y; Ebata, T; Nagino, M

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE   Vol. 35 ( 11 ) page： 2073 - 2080   2020.11

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

Maeda, O; Ohka, F; Maesawa, S; Matsuoka, A; Shimokata, T; Mitsuma, A; Urakawa, H; Nakamura, S; Shimoyamas, Y; Nakaguro, SM; Wakabayashi, T; Ando, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page： 631 - 644   2020.11

Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial

Nishida, Y; Hamada, S; Urakawa, H; Ikuta, K; Sakai, T; Koike, H; Ito, K; Emoto, R; Ando, Y; Matsui, S

CANCER SCIENCE   Vol. 111 ( 11 ) page： 4187 - 4194   2020.11

Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5′-Deoxy-5-fluorocytidine, and Creatinine Clearance

Inaishi, T; Fujita, KI; Matsumoto, N; Shimokata, T; Maeda, O; Kikumori, T; Hattori, N; Nakayama, G; Ando, Y

IN VIVO   Vol. 34 ( 6 ) page： 3539 - 3544   2020.11

Gap between pediatric and adult approvals of molecular targeted drugs

Nishiwaki, S; Ando, Y

SCIENTIFIC REPORTS   Vol. 10 ( 1 ) page： 17145   2020.10

Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer

Minami, H; Ando, Y; Tamura, K; Tajima, T; Isaacs, R

ANTICANCER RESEARCH   Vol. 40 ( 9 ) page： 5229 - 5235   2020.9

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter

Maeda, O; Shimokata, T; Ando, Y

CLINICAL CANCER RESEARCH   Vol. 26 ( 14 ) page： 3889 - 3889   2020.7

Experiences and hidden needs of older patients, their families and their physicians in palliative chemotherapy decision-making: a qualitative study

Tsuboi, R; Sugishita, M; Hirakawa, Y; Ando, Y

JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 50 ( 7 ) page： 779 - 786   2020.7

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Urakawa, H; Ando, Y; Hase, T; Kikumori, T; Arai, E; Maeda, O; Mitsuma, A; Sugishita, M; Shimokata, T; Ikuta, K; Ishiguro, N; Nishida, Y

INTERNATIONAL JOURNAL OF CANCER   Vol. 146 ( 12 ) page： 3504 - 3515   2020.6

Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

Mizuno, K; Ito, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Honda, T; Kawashima, H; Inukai, Y; Toyoda, H; Yokota, K; Hase, T; Maeda, O; Kiyoi, H; Nagino, M; Hibi, H; Kodera, Y; Fujimoto, Y; Sone, M; Gotoh, M; Ando, Y; Akiyama, M; Hasegawa, Y; Fujishiro, M

JOURNAL OF GASTROENTEROLOGY   Vol. 55 ( 6 ) page： 653 - 661   2020.6

Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.

Nishida, Y; Urakawa, H; Nakayama, R; Ozaki, T; Ae, K; Matsumoto, Y; Ando, Y; Kuwatsuka, Y; Ueda, T; Kawai, A

JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 15 )   2020.5

Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.

Miyai, Y; Enomoto, A; Ando, Y; Takahashi, M

JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 15 )   2020.5

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Okada, N; Iwama, S; Okuji, T; Kobayashi, T; Yasuda, Y; Wada, E; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Hase, T; Morise, M; Kanda, M; Yokota, K; Hashimoto, N; Ando, M; Fujimoto, Y; Nagino, M; Kodera, Y; Fujishiro, M; Hibi, H; Sone, M; Kiyoi, H; Gotoh, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

BRITISH JOURNAL OF CANCER   Vol. 122 ( 6 ) page： 771 - 777   2020.3

Detection of bacteria in blood circulation in patients receiving cancer chemotherapy

Ota, A; Morita, S; Matsuoka, A; Shimokata, T; Maeda, O; Mitsuma, A; Yagi, T; Asahara, T; Ando, Y

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 25 ( 1 ) page： 210 - 215   2020.1

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

Kobayashi, T; Iwama, S; Yasuda, Y; Okada, N; Okuji, T; Ito, M; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Yokota, K; Hase, T; Morise, M; Hashimoto, N; Ando, M; Fujimoto, Y; Hibi, H; Sone, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

JOURNAL FOR IMMUNOTHERAPY OF CANCER   Vol. 8 ( 2 )   2020

Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan

Nishiwaki, S; Ando, Y

JOURNAL OF GLOBAL ONCOLOGY   Vol. 5   page： 1 - 3   2019.11

A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

Matsuoka, A; Mitsuma, A; Maeda, O; Tsunoda, N; Kikumori, T; Ando, Y

ANNALS OF ONCOLOGY   Vol. 30   2019.10

Selection of chemotherapy based on geriatric assessment for elderly patients with pancreatic cancer

Maeda, O; Matsuoka, A; Yanagawa, M; Muroyama, Y; Kuzuya, M; Ando, Y

ANNALS OF ONCOLOGY   Vol. 30   page： 131 - 131   2019.10

Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

Wick, W; Tabatabai, G; Schuler, M; Rorhberg, K; Chawla, SP; Janku, F; Schiff, D; Heinemann, V; Narita, Y; Ando, Y; Lenz, HJ; Ikeda, M; Genvresse, I; Rentzsch, C; Reschke, S; Cyris, C; Cai, C; Jeffers, M; Pena, C; Bähr, O

ANNALS OF ONCOLOGY   Vol. 30   page： 170 - +   2019.10

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

Maeda, O; Ando, Y

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY   Vol. 11 ( 7 ) page： 518 - 526   2019.7

Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy

Maeda, O; Matsuoka, A; Furukawa, K; Miyahara, R; Hirooka, Y; Ando, Y

MOLECULAR AND CLINICAL ONCOLOGY   Vol. 11 ( 1 ) page： 91 - 98   2019.7

Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.

Nishida, Y; Sakai, T; Shimizu, K; Urakawa, H; Arai, E; Ikuta, K; Ando, Y; Ishiguro, N

JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 15 )   2019.5

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Wirth, LJ; Leboulleux, S; Kiyota, N; Tahara, M; Muro, K; Ahn, MJ; Ando, Y; Taylor, MH; Takahashi, S; Kim, SB; Misir, S; Dutcus, CE; Xie, R; Joshi, PR; Hughes, BGM; Aller, J; Krzyzanowska, MK; Capdevila, J

JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 15 )   2019.5

Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study

Takano, N; Yamada, S; Hirakawa, A; Yokoyama, Y; Kawashima, H; Maeda, O; Okada, T; Ohno, E; Yamaguchi, J; Ishikawa, T; Sonohara, F; Suenaga, M; Takami, H; Hayashi, M; Niwa, Y; Hirooka, Y; Ito, Y; Naganawa, S; Ando, Y; Nagino, M; Goto, H; Fuji, T; Kodera, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 2 ) page： 233 - 239   2019.5

Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors

Ando, Y; Iwasa, S; Takahashi, S; Saka, H; Kakizume, T; Natsume, K; Suenaga, N; Quadt, C; Yamada, Y

CANCER SCIENCE   Vol. 110 ( 3 ) page： 1021 - 1031   2019.3

Modified Docetaxel plus Cisplatin plus Capecitabine (DCX) for Gastric Cancer

Maeda, O; Ando, Y; Matsuoka, A; Furukawa, K; Funasaka, K; Miyahara, R; Hirooka, Y; Goto, H

DIGESTION   Vol. 99 ( 1 ) page： 113 - 113   2019

Spiritual pain and care needs of elderly cancer patients facing palliative chemotherapy decision-making: Qualitative study.

Tsuboi, R; Sugishita, M; Hirakawa, H; Ando, Y

JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 34 )   2018.12

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma

Yonemori, K; Kodaira, M; Satoh, T; Kudo, T; Takahashi, S; Nakano, K; Ando, Y; Shimokata, T; Mori, J; Inoue, K; Oakley, GJ; Sakaguchi, S; Tamura, K

CANCER SCIENCE   Vol. 109 ( 12 ) page： 3962 - 3970   2018.12

Reporting harms more transparently in trials of cancer drugs

Gyawali, B; Shimokata, T; Honda, K; Ando, Y

BMJ-BRITISH MEDICAL JOURNAL   Vol. 363   page： k4383   2018.11

Cabozantinib in Hepatocellular Carcinoma

Maeda Osamu, Ando Yuichi

NEW ENGLAND JOURNAL OF MEDICINE   Vol. 379 ( 14 ) page： 1384 - 1384   2018.10

Cabozantinib in Hepatocellular Carcinoma.

Maeda O, Ando Y

The New England journal of medicine   Vol. 379 ( 14 ) page： 1384   2018.10

A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

Matsuoka, A; Maeda, O; Mitsuma, A; Uehara, K; Nakayama, G; Nagino, M; Kodera, Y; Ando, Y

ANNALS OF ONCOLOGY   Vol. 29   2018.10

Docetaxel, cisplatin and fluorouracil as neoadjuvant chemotherapy for esophageal cancer with prophylactic pegfilgrastim

Maeda, O; Koike, M; Fukaya, M; Miyata, K; Iwata, N; Nagino, M; Kodera, Y; Ando, Y

ANNALS OF ONCOLOGY   Vol. 29   2018.10

Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

Urakawa, H; Nishida, Y; Mitsuma, A; Maeda, O; Sugishita, M; Shimokata, T; Mizutani, T; Arai, E; Ikuta, K; Hamada, S; Ota, T; Ishiguro, N; Ando, Y

ANNALS OF ONCOLOGY   Vol. 29   2018.10

Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

Ando, Y; Doi, T; Mitsuma, A; Mizutani, T; Toyoda, M; Imamura, Y; Kiyota, N; Naito, Y; Matsubara, N; Ishihara, K; Tajima, T; Tokushige, K; Cameron, S; Minami, H

ANNALS OF ONCOLOGY   Vol. 29   2018.10

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

Nakayama, G; Mitsuma, A; Sunagawa, Y; Ishigure, K; Yokoyama, H; Matsui, T; Nakayama, H; Nakata, K; Ishiyama, A; Asada, T; Umeda, S; Ezaka, K; Hattori, N; Takami, H; Kobayashi, D; Tanaka, C; Kanda, M; Yamada, S; Koike, M; Fujiwara, M; Fujii, T; Murotani, K; Ando, Y; Kodera, Y

ONCOLOGIST   Vol. 23 ( 8 ) page： 919 - 927   2018.8

Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer

Yamada, S; Fujii, T; Yokoyama, Y; Kawashima, H; Maeda, O; Suzuki, K; Okada, T; Ono, E; Yamaguchi, J; Takano, N; Takami, H; Hayashi, M; Niwa, Y; Hirooka, Y; Ito, Y; Naganawa, S; Ando, Y; Nagino, M; Goto, H; Kodera, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 81 ( 5 ) page： 815 - 821   2018.5

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H

Journal of the Endocrine Society   Vol. 2 ( 3 ) page： 241 - 251   2018.3

Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Reviewed

Hiroaki Tsukuura, Masayuki Miyazaki, Tatsuya Morita, Mihoko Sugishita, Hiroshi Kato, Yuka Murasaki, Bishal Gyawali, Yoko Kubo, Masahiko Ando, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa and Yuichi Ando

Oncologist   Vol. 23 ( 3 ) page： 367 - 374   2018.3

Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).

Ezaka, K; Nakayama, G; Yokoyama, H; Matsui, T; Umeda, S; Sunagawa, Y; Murotani, K; Ando, Y; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 4 )   2018.2

Randomized phase II trial of CapOX plus bevacizumab versus CapIRI plus bevacizumab as first-line treatment in Japanese patients with metastatic colorectal cancer (CCOG-1201).

Sasahara, M; Nakayama, G; Ishigure, K; Yokoyama, H; Uehara, K; Ishiyama, A; Matsui, T; Nakayama, H; Kobayashi, D; Umeda, S; Sunagawa, Y; Murotani, K; Ando, Y; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 4 )   2018.2

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan. Reviewed

Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takehumi Mizutani, Tomoya Shimokata, Hiromichi Hayashi, Osamu Maeda and Yuichi Ando

Int J Clin Oncol   Vol. 23 ( 1 ) page： 195 - 200   2018.2

Guidelines for treatment of renal injury during cancer chemotherapy 2016

Horie, S; Oya, M; Nangaku, M; Yasuda, Y; Komatsu, Y; Yanagita, M; Kitagawa, Y; Kuwano, H; Nishiyama, H; Ishioka, C; Takaishi, H; Shimodaira, H; Mogi, A; Ando, Y; Matsumoto, K; Kadowaki, D; Muto, S

CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 22 ( 1 ) page： 210 - 244   2018.2

Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer. Reviewed

Naomi Hayashi, Ayumu Matsuoka, Hidemi Goto, Momokazu Gotoh, Hitoshi Kiyoi, Yasuhiro Kodera, Masato Nagino, Fumio Nagashima, Yuichi Ando.

J Geriatr Oncol   Vol. 9 ( 1 ) page： 84 - 86   2018.1

Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

Maeda, O; Yokoyama, Y; Yamaguchi, J; Ota, A; Matsuoka, A; Morita, S; Inoue, M; Mizutani, T; Shimokata, T; Urakawa, H; Mitsuma, A; Nagino, M; Ando, Y

ANNALS OF ONCOLOGY   Vol. 28   page： 69 - 69   2017.11

FDA Approval Summary: Sonidegib-Letter

Gyawali, B; Ando, Y

CLINICAL CANCER RESEARCH   Vol. 23 ( 19 ) page： 5993 - 5993   2017.10

Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis

Maeda, O; Shimokata, T; Mizutani, T; Inoue, M; Matsuoka, A; Ota, A; Mizuno, T; Ebata, T; Nagino, M; Ando, Y

ANNALS OF ONCOLOGY   Vol. 28   page： 50 - 50   2017.10

Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors

Gyawali, B; Shimokata, T; Ando, Y

ANNALS OF ONCOLOGY   Vol. 28   2017.9

A phase 1 study of BYL719, an a-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies

Tomomatsu, J; Iwasa, S; Saka, H; Takahashi, S; Nakano, K; Morita, S; Inoue, M; Nakahama, H; Kogure, Y; Kakizume, T; Natsume, K; Aoki, T; Quadt, C; Yamada, Y; Ando, Y

ANNALS OF ONCOLOGY   Vol. 28   2017.9

Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

Molecular and clinical oncology   Vol. 7 ( 3 ) page： 510   2017.9

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Nakayama, G; Ishigure, K; Yokoyama, H; Uehara, K; Kojima, H; Ishiyama, A; Hayashi, N; Takano, N; Hattori, N; Kobayashi, D; Tanaka, C; Hayashi, M; Kanda, M; Yamada, S; Sugimoto, H; Koike, M; Fujiwara, M; Fujii, T; Murotani, K; Ando, Y; Kodera, Y

BMC CANCER   Vol. 17 ( 1 ) page： 243   2017.4

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

Gyawali, B; Ando, Y

ANNALS OF ONCOLOGY   Vol. 28 ( 4 ) page： 898 - 899   2017.4

Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi

BREAST CANCER   Vol. 24 ( 2 ) page： 312 - 318   2017.3

[Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].

Matsuoka A, Ando Y

Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 44 ( 3 ) page： 200 - 203   2017.3

Modified docetaxel, cisplatin and capecitabine for stage. gastric cancer in Japanese patients: A feasibility study

Maeda, O; Matsuoka, A; Miyahara, R; Funasaka, K; Hirooka, Y; Fukaya, M; Nagino, M; Kodera, Y; Goto, H; Ando, Y

WORLD JOURNAL OF GASTROENTEROLOGY   Vol. 23 ( 6 ) page： 1090 - 1097   2017.2

Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials

Gyawali, B; Shimokata, T; Ando, M; Honda, K; Ando, Y

ANNALS OF ONCOLOGY   Vol. 28 ( 2 ) page： 246 - 253   2017.2

Unconvincing Benefit of Combination TherapyWith Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer

Ota, A; Gyawali, B; Matsuoka, A; Ando, Y

JOURNAL OF CLINICAL ONCOLOGY   Vol. 35 ( 6 ) page： 691 - +   2017.2

[Analysis of Nedaplatin Dose in Patients with Impaired Renal Function].

Araki R, Iwamizu H, Kataoka T, Kumakura Y, Miyazaki M, Nagai T, Ando Y, Yamada K

Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 44 ( 2 ) page： 143 - 147   2017.2

Carboplatin dosing for adult Japanese patients Invited Reviewed

Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, and Yoshinori Hasegawa.

Nagoya J Med Sci   Vol. 76 ( 1 ) page： 1-9   2014.2

A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Reviewed

Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi.

Cancer Sci   Vol. 105 ( 3 ) page： 347-53   2014.1

Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed

Cancer Sci   Vol. 101   page： 2601-5   2010

UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Invited Reviewed

Yuichi Ando, et al.

Curr Opin Mol Ther   Vol. 9   page： 258-262   2007

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Reviewed

Yuichi Ando, et al.

Cancer Res   Vol. 60   page： 6921-6926   2000

Mechanism of predicting the effects of immune checkpoint inhibitors based on the diversity of cancer-associated fibroblasts

Grant number：20H03528  2020.4 - 2023.3

Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

Ando Yuichi

がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出

Grant number：19K07083  2019.4 - 2024.3

科学研究費助成事業  基盤研究(C)

満間 綾子, 安藤 雄一, 下方 智也

Factors involved in the efficacy and safety of biopharmaceuticals

Grant number：19K07224  2019.4 - 2022.3

Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

Nakamura Katsunori

Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment

Grant number：17K08950  2017.4 - 2020.3

Ando Yuichi

Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.

Grant number：16K08906  2016.4 - 2020.3

Mitsuma Ayako

Study of the infusion reaction by rituximab

Grant number：16K08374  2016.4 - 2019.3

Nakamura Katsunori

Elucidation of sarcopenia mechanism in the cancer cachexia

Grant number：15K08906  2015.4 - 2019.3

Shimokata Tomoya

Clinical significance of sarcopenia in cancer chemotherapy

Grant number：26460626  2014.4 - 2018.3

Ando Yuichi

Establishment of bone metastasis treatment by regulating hyaluronan network and osteoclast

Grant number：26462261  2014.4 - 2018.3

Urakawa Hiroshi

がん薬物療法における血管新生阻害薬の薬物効果予測因子としての眼底所見の探索的研究

2011.4 - 2013.3

科学研究費補助金  基盤研究(C)

がん薬物療法における薬剤誘発性ＱＴ延長の遺伝的要因を含めた患者要因　　　　　　　

2008.4 - 2011.3

科学研究費補助金  基盤研究(C)

安藤　雄一